Jerome Burne and Bio-Identical Hormone Replacement Therapy: Parts 1 and 2 covered some difficulties with Kent Holtorf’s review article, Are Bioidentical Hormones (Estradiol, Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy?, relating to a potential conflict of interest (despite a statement to the contrary) and the completeness and quality of the review. For this final examination of Jerome Burne’s Should middle-aged women be taking natural HRT?, we focus on a paper for which we had to guess the identity: Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. (Again, This Really Is Not Good Enough or TRINGE.) Continue reading
Tag Archives: cardiovascular disease
The Journal of the American Medical Association has recently published a good quality, placebo-controlled, randomised, double-blind trial looking at whether vitamin C and E supplementation can reduce cardiovascular events. It ran for 10 years, and included “14 641 US male physicians enrolled, who were initially aged 50 years or older, including 754 men (5.1%) with prevalent cardiovascular disease at randomization.” The trial concluded that “[t]hese data provide no support for the use of these supplements for the prevention of cardiovascular disease in middle-aged and older men.”
I was surprised to see that the alternative nutrition industry has not yet responded to this – I was waiting with bated breath for Sir Cliff Richard’s definitive critique of the science – so I thought that I would respond on their behalf: frankly, the alternative nutrition industry’s response to such trials has become tediously predictable so there seems to be little point in waiting.
I will list a number of likely industry responses below; I will then enjoy the small satisfaction of ticking them off when they appear in industry press releases: Continue reading
Former Visiting Professor Patrick Holford is still Head of Science and Education at Biocare so presumably they must believe that he enhances their reputation and scientific credibility with his advocacy of tests such as those for homocysteine (Hcy) levels and recommendations that people with high levels (as defined by him) should lower it by taking various supplements (see related reading). Continue reading
Visiting Professor Patrick Holford of Teesside University and Head of Science and Education at Biocare has an odd relationship with statins. Who can forget his straight-to-camera overview of Big Pharma’s “full spectrum dominance” and the industrial complex that enforces mass-medication with prescription drugs such as statins. Or his shocked (and incorrect) assertion that “almost 20,000 people have to take a statin for 5 years for 1 less heart attack”. It could never have made sense to anyone who gave the matter half a second’s thought, far less someone who styles himself as leading health expert, but there you have it: Visiting Professor at the University of Teesside and able to make that statement with a rather unnerving (and misplaced) sincerity. Regular readers will not be surprised to learn that Holford sees the just announced and updated NICE Clinical Guidelines as yet another opportunity to decry Big Pharma’s profits relating to statins and to promote niacin: you may, however, be interested in an upcoming plot twist. Continue reading